Posts tagged Alan Carr


Tetraphase Pharmaceuticals Inc (TTPH) Investors Are Parading Today, But Needham Cautious on the Long-Term

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) shares are jumping up close to 16% after the drug maker …

Genocea Biosciences Inc (GNCA): This Analyst Turns Bullish, Sets $12 Target Price

In a research report issued Monday, Needham analyst Alan Carr upgraded shares of Genocea Biosciences Inc (NASDAQ:GNCA), …

FDA AdCom Meeting Cancellation for Neurocrine Biosciences, Inc. (NBIX) Ingrezza NDA Positive News: Needham Analyst

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares are on a 7% rise after the company revealed yesterday …

Needham Likes Genocea Biosciences Inc (GNCA) Potential for Upside Following R&D Day; Shares Rise 8%

Genocea Biosciences Inc (NASDAQ:GNCA) shares are surging nicely ahead 8% today after the firm hosted …

Needham’s Alan Carr Turns Bullish on Achaogen Inc (AKAO); Here’s Why

Achaogen Inc (NASDAQ:AKAO) shares were shooting through the roof at 148% yesterday after the biotech …

Here’s Why Needham Downgraded Cempra Inc (CEMP) Shares Today

In a research report released Friday, Needham analyst Alan Carr downgraded shares of Cempra Inc …

Needham Reiterates Hold on Arena Pharmaceuticals, Inc. (ARNA) Following 3Q:16 Update

In a research report issued Tuesday, Needham analyst Alan Carr reiterated a Hold rating on Arena …

Needham Bullish on ACADIA Pharmaceuticals Inc. (ACAD) Following Nuplazid Discussion with KOL

Needham analyst Alan Carr weighs in on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) after hosting a call …

Analysts Weigh in on Volatile Biotech Stocks: Alnylam Pharmaceuticals, Inc. (ALNY) and Aurinia Pharmaceuticals (AUPH)

Analysts offer insights into a volatile biotech-verse amid Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares dipping on news of …

Needham Reiterates Buy on Lexicon Pharmaceuticals Inc. Following Phase 3 Results in Type 1 Diabetes

In a research report issued Friday, Needham analyst Alan Carr reiterated a Buy rating on …

Show More